Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Accumulated Expenses (2016 - 2025)

Haemonetics has reported Accumulated Expenses over the past 16 years, most recently at $52.1 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $52.1 million for Q4 2025, up 13.42% from a year ago — trailing twelve months through Dec 2025 was $52.1 million (up 13.42% YoY), and the annual figure for FY2025 was $59.4 million, down 26.37%.
  • Accumulated Expenses for Q4 2025 was $52.1 million at Haemonetics, up from $48.3 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for HAE hit a ceiling of $80.7 million in Q1 2024 and a floor of $30.4 million in Q3 2022.
  • Median Accumulated Expenses over the past 5 years was $46.8 million (2021), compared with a mean of $47.6 million.
  • Biggest five-year swings in Accumulated Expenses: surged 40.52% in 2021 and later decreased 26.37% in 2025.
  • Haemonetics' Accumulated Expenses stood at $41.1 million in 2021, then grew by 27.07% to $52.2 million in 2022, then rose by 12.61% to $58.8 million in 2023, then fell by 21.83% to $45.9 million in 2024, then grew by 13.42% to $52.1 million in 2025.
  • The last three reported values for Accumulated Expenses were $52.1 million (Q4 2025), $48.3 million (Q3 2025), and $35.8 million (Q2 2025) per Business Quant data.